Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2026-07-09 16:54:03 ET · period of report 2026-07-08 · accession 0001193125-26-299803 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-09 16:54 | 2026-07-08 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $6.38 | +32.4K | 517.2K | +7% | +$206.6K |
| DT | 2026-07-09 16:54 | 2026-07-08 | SNDX | Metzger Michael A | CEO, Dir | S - Sale+OE | $24.24 | -32.4K | 484.8K | -6% | -$784.8K |
| DT | 2026-07-09 16:54 | 2026-07-08 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $0.00 | +32.4K | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-08 | M | A | 32,375 | $6.38 | 517,218 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-08 | S | D | 32,375 | $24.24 | 484,843 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested. (F2) The sale prices ranged from $24.00 to $24.43 |
| 3 | Derivative | Stock Option (Right to buy) | 2026-07-08 | M | A | 32,375 | $0.00 | 0 | D | $6.38 · — to 2029-02-06 | 32,375 Common Stock | (F3) This option is fully vested. |